Immunogenicity and Safety Study of 1 and 2 Doses of Meningococcal Vaccine MenACWY-TT in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13® Vaccine

Immunogenicity and Safety Study of 1 and 2 Doses of Meningococcal Vaccine MenACWY-TT in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13® Vaccine. Supplemental Report (Year 5 hSBA Immunogenicity) to Final Report: A Phase III, Randomised, Open, Controlled, Multicentre, Primary Vaccination Study to Evaluate the Immunogenicity and Persistence of 1 and 2 Doses of Meningococcal Conjugate Vaccine MenACWY-TT in Toddlers (After 1 Month and up to 5 Years) and to Demonstrate Non-Inferiority of Co-Administration of MenACWY-TT and 13-Valent Pneumococcal Conjugate Vaccine Prevenar 13 Versus Separate Administration of the 2 Vaccines.

Category & Conditions:
Vaccine-related Conditions
Medicine:
Nimenrix (meningococcal serogroups A, C, W-135 and Y conjugate vaccine)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
C0921003
Open Plain Language Summary Result:Click here